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The cyclophilins are a group of proteins with peptidyl-prolyl
isomerase enzymatic activity, localised in different cellular com-
partments and involved in a variety of functions related to cell
metabolism and energy homeostasis, having enhanced expres-
sion in inﬂammation or malignancy. Cyclophilin A (CypA), the
most abundantly expressed cyclophilin, is present mainly in the
cytoplasm and is a host factor involved in the life cycle of multi-
ple viruses. The extracellular fractions of CypA and CypB are
potent pro-inﬂammatory mediators. CypD, located in mitochon-
dria, is a key regulator of mitochondrial permeability transition
pores, and is critical for necrotic cell death. Cyclosporines are
the prototype cyclophilin inhibitors. Cyclic peptides, which bind
and inhibit cyclophilins without having immunosuppressive
properties, have been generated by chemical modiﬁcations of
cyclosporin A. In addition, cyclophilin inhibitors that are structur-
ally different from cyclosporines have been synthesized. The
involvement of cyclophilins in the pathogenesis of different liver
diseases has been established using both in vitro and in vivo
investigations, thus indicating that cyclophilin inhibition may
be of therapeutic beneﬁt. This review summarises the evidence
for potential therapeutic applications of non-immunosuppressive
cyclophilin inhibitors, alone or in combination with other agents,
in virus-induced liver diseases like hepatitis C, B or Delta, liver
inﬂammation and ﬁbrosis, acetaminophen-induced liver toxicity
and hepatocellular carcinoma.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Cyclophilins are a group of cellular proteins (collectively known
as immunophilins), which display the enzymatic activity of a
peptidyl-prolyl isomerase (PPIase) [1,2]. This enzyme catalyses
the cis to trans conversion of proline-containing peptides
and facilitates protein folding. Cyclophilins are ubiquitouslyJournal of Hepatology 20
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E-mail address: nikolai.naoumov@novartis.com.expressed in all prokaryotic and eukaryotic cells. The ﬁrst cyclo-
philin was identiﬁed in 1984 as a speciﬁc cytosolic protein that
binds cyclosporin A (CsA) [3]. However it was not until 5 years
later, in 1989, that it was demonstrated that the 18 kDa protein
with PPIase activity and cyclophilin (CypA) were in fact the same
protein [4,5].
Overall, 17 cyclophilins have been identiﬁed in the human
genome, however the function of most of these is unknown and
only 7 have been characterised for isomerase activity or binding
to CsA [1,2]. Cyclophilins share a common domain of approxi-
mately 109 amino acids, the cyclophilin-like domain, which is
surrounded by domains unique to each member of the family
and associated with their subcellular compartmentalization and
functional specialization. The subcellular localization of some
cyclophilins has been deﬁned, for example – CypA (Cyp18a,
where 18 denotes its molecular mass of 18 kDa) and Cyp40
(40 kDa) are present in the cytosol; CypB (22 kDa) and CypC
reside in the lumen of the endoplasmic reticulum; CypD – in
mitochondria; CypE and CypA are found in the nucleus [1].
CypNK, a 150 kDa molecule, was identiﬁed on the surface of
human natural killer cells [6].
During the last 20 years considerable knowledge has been
accumulated for CypA, CypB, and CypD – concerning their
involvement in speciﬁc cell functions and disease pathogenesis,
while the functional characterization of other members of the
cyclophilin family and potential roles in diseases have not been
elucidated. CypA is one of the most abundant proteins in the
cytoplasm (approximately 0.1% of total cytosolic proteins) and
is involved in a range of cellular functions including protein fold-
ing, trafﬁcking, immunomodulation and cell signalling [7]. The
development of CypA knockout mice and CypA knockdown cell
lines has demonstrated that CypA is not essential for cell growth
and survival [8,9]. Importantly, CypA is secreted from cells spon-
taneously and in response to inﬂammatory stimuli or oxidative
stress (reviewed in [10]), and the extracellular fraction of CypA
acts as a potent pro-inﬂammatory mediator, which stimulates
inﬂammatory responses and exerts chemotactic activity for neu-
trophils and monocytes via the CD147 cell receptor (Table 1).
Increased CypA expression has a major role in various patholog-
ical conditions such as inﬂammatory reactions and cartilage
destruction in rheumatoid arthritis [18–20]; progression of
inﬂammatory diseases in the lung [24]; exacerbation of oxidative
stress and inﬂammation [21,22]. CypA is also overexpressed in
cancer cells and promotes metastasis [27,28].
CypB was the second cyclophilin identiﬁed [29]. It differs from
CypA mainly by the presence of a cleavable N-terminal sequence14 vol. 61 j 1166–1174
Table 1. Key functions of cyclophilin A.
Functions Target Biological/pathological effects [Ref.]
Intracellular
Protein folding
Protein trafficking
Stimulates proinflammatory signals
Chemotaxis of inflammatory cells
Collagen
Transferrin
Folding of pro-collagen 1
Folding of transferrin
11
12
Heterogenous nuclear RNP A2 
CD147
Asialoglycoprotein receptor (ASGPR)
CXCR4-mediated export of hnRNPA2 
Transport to plasma membrane
ASGPR transport between plasma 
Regulation of T-helper cell profile and 
Promotes joint inflammation in rheumatoid 
Stimulates inflammatory responses when 
membrane and endosomal pool
13
14
15
T-cell activation, cell signaling Interleukin-2 tyrosine kinase (Itk) 
VCAM-1, E-selectin
cytokines 
Proliferation and migration of vascular 
smooth muscle cells
8,16
17
Extracellular
MMP-2, MMP-9
Interleukin-8 arthritis, degradation of joint cartilage
18,19,20
Exacerbate oxidative stress Vascular smooth muscle cells Oxidative stress 21,22
CD147/EMMPRIN Potent leukocyte chemoattractant for human 
monocytes, neutrophils, eosinophils, and 
T cells 
injected in vivo
Stimulates expression of adhesion molecules
14,23,24
23
25,26
hnRNPA2, heterologous nuclear ribonucleoprotein A2; VCAM-1, vascular cell adhesion molecule 1; MMP, metalloproteinase; NF-KB, nuclear factor kappa B; EMMPRIN,
extracellular matrix metalloproteinase inducer, or CD147.
Closed PTP Closed PTPOpen PTP
Fig. 1. Cyclophilin D (CyP-D) regulates opening of the mitochondrial perme-
ability transition pore (PTP). (i) CyP-D phosphorylation by GSK3 facilitates PTP
opening; (ii) phosphorylated STAT3 binds to CyP-D and inhibits PTP opening; (iii)
CyP-D acetylation sensitizes the PTP to opening and is prevented by AMPK
activation of the SIRT3 de-acetylase. Reprinted from [33]  2014, with permission
from Elsevier.
JOURNAL OF HEPATOLOGYthat directs the protein to the endoplasmic reticulum. CsA, and
other cyclophilin inhibitors, speciﬁcally mobilize CypB from the
endoplasmic reticulum and promote its secretion from cells, with
the extracellular CypB fraction lacking the N-terminal signal
sequence [30]. Unlike CypB, CypA is not secreted upon adminis-
tration of cyclophilin inhibitors. The extracellular fractions of
CypA and CypB are involved in cell-cell communications and
inﬂammatory signalling, however on its own, CypB seems unable
to induce proinﬂammatory cytokines [10].
CypD is another key cyclophilin, which is located in the mito-
chondria and has a central role in regulating the mitochondrial
permeability transition pore (MPTP), hence it has been consid-
ered as potential therapeutic target for different diseases where
mitochondrial dysfunction is central to the disease pathogenesis
[31,32]. Mitochondria can be considered as a ‘‘ﬁrewall’’ that con-
trols the Ca2+ concentration in different cell compartments.
Across the outer mitochondrial membrane, the Ca2+ transport is
mediated mainly by the poorly selective voltage-dependent
anion channel (VDAC). Across the inner membrane, the uptake
of Ca2+ occurs through the mitochondrial Ca2+ uniporter and/or
the rapid uptake mode, while MPTP has a major role for
Ca2+ efﬂux from mitochondria to the cytosol [33]. When opened
in a ﬂickering mode, the MPTP acts as a fast Ca2+ release channel,
generating waves of cytosolic Ca2+ that propagate signals to other
cell regions or are taken up by surrounding mitochondria. CypD is
localized in the matrix of mitochondria and regulates MPTP
opening and consequently the Ca2+ exchange between the
mitochondria and the cytosol (Fig. 1). Several lines of evidence
from experiments using hepatocytes, neurons or cardiomyocytes
have established that CypD, is the key regulator of MPTP opening
[32,33]. A persistent MPTP opening induces necrotic cell death,
which is different from necroptosis – a regulated cell necrosisJournal of Hepatology 2014that is dependent on the receptor-interacting protein kinase 3,
RIPK3 [34]. Recently, it has been shown that cell necrosis, as a
result of mitochondrial permeability transition or necroptosis,
occurs via two co-existing but separate pathways, and the com-
bined blockade of both pathways, – such as CypD inhibition with
cyclosporine or a non-immunosuppressive Cyp inhibitor (sang-
lifehrin A) together with necroptosis inhibition with the RIPK1
inhibitor necrostatin-1, has resulted in strong and additive pro-
tection from ischemia-reperfusion injury [34,35]. CypD plays avol. 61 j 1166–1174 1167
Review
fundamental role in the overall energy homeostasis in cells. The
deﬁnitive proof that CypD is critical for necrotic signalling was
provided in 2005 using the genetic deletion of Ppif (the CypD
gene) [36]. These studies found that Ppif-null cells are highly
resistant to cell death induced by cytosolic Ca2+ overload and
hydrogen peroxide-mediated ROS stress.
The involvement of cyclophilins in the pathogenesis of differ-
ent liver diseases has been established in both in vitro and in vivo
investigations, thus, indicating that cyclophilin inhibition may be
of therapeutic beneﬁt. This review summarises the evidence for
potential therapeutic applications of non-immunosuppressive
cyclophilin inhibitors in liver diseases.
Key Points
• Cyclophilins are ubiquitous cellular proteins with 
peptidyl-prolyl isomerase enzymatic activity, which 
are involved in a variety of functions related to cell 
metabolism, energy homeostasis, and have enhanced 
expression in inflammation or malignancy
• Small molecules that bind and inhibit cyclophilins have 
been generated either as non-immunosuppressive 
derivatives of cyclosporin A, or as molecules that are 
structurally distinct from cyclosporines
• Blocking cyclophilin A has been shown to result in a 
potent antiviral effect against a range of viruses, with 
the largest in vitro and clinical database available for 
hepatitis C virus. In addition, blocking cyclophilin A 
has an anti-inflammatory effect and reduces its role in 
oxidative stress and chemotaxis of inflammatory cells
• Blocking cyclophilin D is effective in correcting 
pathological conditions that involve mitochondrial 
dysfunction, oxidative stress or cell necrosis
• Cyclophilin inhibitors alone or in combination with other 
agents, could be beneficial in the treatment of chronic 
hepatitis C, chronic hepatitis B, acetaminophen-induced 
liver toxicity; they may reduce liver inflammation 
and fibrosis in non-alcoholic steatohepatitis, 
possibly augment activity of chemotherapy against 
hepatocellular carcinoma and decrease the metastatic 
spreadCyclophilin inhibitors: Structure and functional relationships
Cyclosporin A
The story of cyclophilin inhibitors began in 1970 when cyclo-
sporin A (CsA) and cyclosporin C were isolated from the fungus
Tolypocladium inﬂatum and found to suppress T-lymphocyte reac-
tivity. CsA is a cyclic peptide comprising of 11 amino acids and its
immunosuppressive action is exerted by forming a ternary com-
plex between CsA, CypA and calcineurin [37]. CsA-induced
immunosuppression is not a result of its binding to CypA, but
from the interaction between the CypA-CsA complex with calci-
neurin, as the latter is required for T cell activation [1,9,38]. For-
mation of this ternary complex leads to inhibition of the intrinsic
phosphatase activity of calcineurin, which abolishes the nuclear
translocation of the nuclear factor of activated T cells (NFAT). This1168 Journal of Hepatology 2014ultimately contributes to the failure of T cells to respond to anti-
genic stimuli [1,38].
Non-immunosuppressive cyclophilin inhibitors
Cyclophilin inhibitors with non-immunosuppressive properties
have been generated by chemical modiﬁcations of the CsA mole-
cule to produce alisporivir (DEB025), NIM811 and SCY-635 [9,38].
Alisporivir differs from the parent molecule CsA by purposely
substituting two amino acids - sarcosine with D-alanine at posi-
tion 3, and N-methyl-leucine with N-ethyl-valine at position 4
[39]. Although CypA and alisporivir form a complex with nano-
molar afﬁnity, the resulting binary complex is unable to bind cal-
cineurin. Molecular modelling of a NMR-derived CypA-alisporivir
complex, and further analyses of the CypA-alisporivir-calcineurin
complex, have enabled to deﬁne, at a molecular level, the
non-immunosuppressive properties of alisporivir. Whereas the
calcineurin pocket is optimally occupied by the leucine-4 side
chain, the valine-4 side chain of alisporivir cannot enter this
pocket and impedes the formation of a stable ternary complex
[40]. These ﬁndings established that the N-ethyl-valine at posi-
tion 4 in the cyclic peptide of alisporivir is responsible for the
inability to bind calcineurin, and consequently for the lack of
immunosuppressive activity. The chemical structure of NIM811
differs from CsA by having methyl-isoleucine instead of methyl-
leucine at position 4 [41]; for SCY-635 – the differences from
CsA include a dimethylamino-ethylthio substituent at position
3, plus a hydroxyl group at position 4 [42]. Despite relatively
small variations in the structure of CsA and its non-immunosup-
pressive derivatives, these molecules differ in their activity
against HIV or HCV with marked differences in their EC50 [43,44].
Recently, cyclophilin inhibitors were developed that are not
derived from CsA [9,45]. The family of sanglifehrins includes
sanglifehrin A, B, C, D - a group of naturally occurring cyclophi-
lin-binding polyketides that are structurally distinct from
cyclosporines and are produced by soil Streptomyces bacteria.
The natural sanglifehrins have immunosuppressive activity with
a mechanism of action, which does not involve calcineurin, i.e.,
different from that of CsA, and non-immunosuppressive ana-
logues of sanglifehrin A have been synthesized [46,47]. In addi-
tion, small (100–150 Da) non-peptide cyclophilin inhibitors
have been identiﬁed using a fragment-based drug design
approach by means of nuclear magnetic resonance (NMR) and
X-ray crystallography. Two compounds (F680 and F684) showed
signiﬁcant inhibition of CypA, CypB, and CypD enzymatic
activities. It is notable that these two compounds also exerted
anti-HCV G1b activities and were devoid of cytotoxicity [9].Chronic hepatitis C
The most extensive evidence at present concerns the role of cel-
lular cyclophilins in the replication of hepatitis C virus (HCV).
Experiments using siRNA, proteomic assays, and mRNA proﬁling
have established that several cyclophilins are instrumental for
HCV replication [48].
The effect of cyclophilin inhibition in suppressing HCV repli-
cation was ﬁrst demonstrated by Shimotohno and colleagues
using CsA in cultured hepatoma cells [49]. The antiviral activity
was initially thought to be mediated by blocking CypB. Further
studies extended this ﬁnding by demonstrating that thevol. 61 j 1166–1174
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Fig. 2. Mechanism of action of cyclophilin (Cyp) inhibitors in blocking HCV replication. Cyclophilin A (CypA) binds to its ligand (domain II of the NS5A HCV protein) and
interacts with the HCV replication complex on the membranous web. By blocking the interaction between CypA and NS5A, the cyclophilin inhibitors (alisporivir, NIM811,
SCY-635 or sanglifehrins) abrogate HCV replication. Based on [44,45,55,57,59].
JOURNAL OF HEPATOLOGYnon-immunosuppressive CsA derivatives are even more effective
in blocking HCV replication. Although several cyclophilins appear
to be implicated in HCV replication [48–51], the accumulating
evidence has convincingly demonstrated that CypA is the princi-
pal cyclophilin that is essential for viral replication, and its block-
ade underlines the anti-HCV activity of cyclophilin inhibitors
[52–55]. This is further supported by in vivo data from a recently
developed mouse model supporting the entire HCV life cycle –
the HCV replication was drastically reduced in Ppia knockout
mice (Ppia/), conﬁrming that CypA is an essential cellular
cofactor [56]. The speciﬁc mechanisms how cyclophilin inhibition
abrogates HCV replication have been elucidated by several key
ﬁndings. First, the peptidyl-prolyl isomerase activity of CypA
was shown to be critical for HCV replication [52,53]. Unlike wild
type CypA, isomerase-deﬁcient CypA variants with laboratory-
generated mutations in their hydrophobic pocket are unable to
support HCV replication. The second key ﬁnding was that CypA
binds directly to the HCV nonstructural 5A (NS5A) protein, sug-
gesting that the HCV NS5A protein is the viral ligand for the host
CypA protein [55,57,58]. Importantly, the CypA-NS5A interaction
is conserved among all HCV genotypes, which explains the
pan-genotypic antiviral effect of cyclophilin inhibitors as demon-
strated in clinical studies. The third key ﬁnding is that cyclophilin
inhibitors prevent the formation of and disrupt CypA-NS5A
complexes. All classes of cyclophilin inhibitors - CsA,
non-immunosuppressive CsA derivatives (e.g., alisporivir or
SCY-635), sanglifehrins and sanglifehrin derivatives – block
CypA-NS5A interactions in a dose-dependent manner
[44,45,55,57,59]. Therefore, CypA-NS5A interactions are critical
for HCV replication, and the most direct impact of CypA inhibitors
is the prevention of CypA-NS5A contacts, thus abrogating HCV
replication (Fig. 2). In a recent in vitro testing of anti-HCV activity
of alisporivir or sanglifehrin B in combination with different
direct acting antivirals, we found the strongest synergy in the
combination of a cyclophilin inhibitor with a NS5A inhibitor
[60]. In addition, Ciesek et al. reported that the replication of a
JFH1 full-length replicon (encoding non-structural NS2-NS5B
proteins) was far more sensitive to CypA depletion and inhibition
than subgenomic replicons (encoding non-structural NS3-NS5B
proteins) [61]. The role of NS2 in enhancing HCV sensitivity toJournal of Hepatology 2014cyclophilin inhibitors was recently shown to be indirect, a conse-
quence of reduced replication competence most likely as a result
of NS2-mediated polyprotein cleavage, while NS2 is not a direct
target for CypA inhibitors [62].
The clinical experience with non-immunosuppressive cyclo-
philin inhibitors, as a treatment option for chronic hepatitis C
patients, varies considerably: – NIM811 and SCY-635 have been
administered in proof-of-concept and small exploratory trials
(<50 patients) involving up to 4-weeks treatment with these
compounds; alisporivir has been given to more than 2000 HCV
patients, while there is no clinical data with sanglifehrins at pres-
ent [63–66]. Thus, full treatment results and sustained virologic
response rates are currently available only for alisporivir given
in combination with peg-interferon/ribavirin (Fig. 3), or alispori-
vir plus ribavirin as interferon-free treatment for HCV G2 and G3
patients [67,68].
Based on in vitro data, the cyclophilin inhibitors, provided as
host-targeting antiviral agents, seem promising in combination
with direct-acting antivirals (DAAs) in interferon-free treatment
regimens for hepatitis C. Aside from the NS5B polymerase inhib-
itors, cyclophilin inhibitors are the only class that can provide a
backbone in combination with direct antivirals (protease, non-
nucleoside polymerase or NS5A inhibitors), which rapidly select
resistant strains. The following attributes of cyclophilin inhibitors
can be particularly useful in this context: (1) high barrier to viral
resistance [44]; (2) broad genotype coverage; (3) demonstrated
additive or synergistic antiviral effect and blocking the
emergence of resistance to DAAs [60]; (4) fully active against
all HCV mutants that confer resistance to protease, NS5A and
NS5B polymerase inhibitors [58].
Apart from the antiviral effect in suppressing HCV replication,
as a result of CypA inhibition, cyclophilin inhibitors may provide
additional beneﬁts in improving HCV-infected livers through the
concomitant inhibition of CypD and correcting the HCV-induced
mitochondrial dysfunction. HCV proteins produced in infected
hepatocytes target mitochondria, leading to functional conse-
quences and contributing to HCV-induced liver damage [69].
The HCV core protein was shown to increase the formation of
reactive oxygen species (ROS) and affect calcium uptake and
release. The in vitro treatment of cells transfected with HCV withvol. 61 j 1166–1174 1169
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Fig. 3. Sustained Virologic Response (SVR12) in HCV genotype 1 previous
treatment-failure patients for particular difﬁcult to treat patient subgroups
(with cirrhosis or IL28B genotype CT/TT) who received treatment with
alisporivir (ALV) once daily (QD) or twice daily (BID) in combination with
peg-interferon/ribavirin (P/R). ITT results from the FUNDAMENTAL study 2210
[67].
Reviewalisporivir was able to correct/prevent HCV protein-mediated
mitochondrial dysfunction by blocking CypD, and obtaining an
associated effect on MPTP [70].Chronic hepatitis B
The accumulating evidence indicates that cyclophilins are
involved in the life cycle of the hepatitis B virus (HBV) in hepato-
cytes. Early investigations using an HBx protein-dependent
model for HBV replication in HepG2 cells, have suggested that
changes in mitochondrial calcium ﬂow and blocking cytosolic
calcium signalling can impact HBV replication [71]. Cyclophilin
inhibition (with either CsA or its non-immunosuppressive deriv-
ative NIM811) was shown to interfere with HBV replication by
acting on Ca2+ cytosol levels and speciﬁcally on the mitochondrial
permeability transition pores [71]. More recently, the role of
cyclophilins in liver cells, and the effect of cyclophilin inhibitors
(NIM811, alisporivir or the sangamide-based cyclophilin inhibitor
- NVP018) on HBV replication and HBsAg production were inves-
tigated in greater details [72–74]. The involvement of individual
cyclophilins was investigated after selective knockdown of CypA,
CypC or CypD with speciﬁc siRNA [73]. Cyclophilin expression in
HuH7 cells was markedly reduced (>80%) after transfection with
the corresponding siRNA, which was associated with a signiﬁcant
lowering of HBV-DNA and HBsAg levels. The experiments indi-
cated that CypA is the principal cyclophilin involved in HBsAg
production and secretion; incubation with either alisporivir or
NIM811 reduced HBV replication and HBsAg levels [72,73]. The
effects of cyclophilin inhibition on HBV life cycle were further
supported by in vitro and in vivo animal data using a sanga-
mide-based cyclophilin inhibitor - NVP018 [74]. Two-week
administration of NPV018 in a mouse HBV model resulted in a
1.2–1.5 log reduction of serum HBV DNA levels along with a
decrease in HBsAg titres. HBsAg and CypA are closely associated
during secretion from liver cells [75], thus disrupting the CypA/
HBsAg complex by cyclophilin inhibitors will be one possible
mechanism for reducing the envelope protein secretion.1170 Journal of Hepatology 2014Collectively, the available data indicate that cyclophilin inhibi-
tion with either non-immunosuppressive analogues of CsA or
with a sanglifehrin-based inhibitor could be useful in the
treatment of patients with chronic hepatitis B, potentially also
for hepatitis Delta, as they interfere at multiple sites of the HBV
life cycle and HBsAg: ﬁrst, within the hepatocytes by blocking
CypA and CypD, cyclophilin inhibitors will reduce HBV DNA
replication as well as HBsAg production/secretion; secondly
and independent of the cyclophilin inhibition, by blocking the
sodium-taurocholate co-transporter polypeptide (NTCP) on the
hepatocyte membrane, recently shown to be a speciﬁc receptor
for HBV and hepatitis Delta virus [76–78], cyclophilin inhibitors
would prevent the entry of these viruses into cells, and infection
of new hepatocytes. The potential beneﬁt of combining a
cyclophilin inhibitor with some of the well-established HBV
antiviral agents will need to be tested in clinical studies to assess
whether it will accelerate and/or enhance HBsAg clearance.Mitochondrial dysfunction in liver diseases and cyclophilin
inhibition
The term ‘‘mitochondrial medicine’’ was introduced recently and
refers to treatment approaches that are directed at preventing
and/or treating mitochondrial dysfunction and its consequences
[79]. Mitochondria play a key role in the normal function and
the integrity of liver cells and a wide range of liver diseases are
associated with mitochondrial dysfunction. As outlined in the
introduction, CypD regulates the opening of MPTP and calcium
exchange between the mitochondrial space and the cytosol and
has a key role in cell necrosis or necroptosis [33,34]. Thus, CypD
inhibition might be beneﬁcial for the liver in preventing a cascade
of events, triggered by mitochondrial dysfunction, and leading to
cell death.
Liver regeneration
Mitochondrial calcium was recently shown to play a role in liver
regeneration after partial hepatectomy [80]. Mitochondrial per-
meability transition underlies the dysfunction of small-for-size
livers. Transplantation of quarter-size livers has been associated
with liver cell necrosis, increase in ALT and bilirubin levels. In an
experimental model, these were reduced by 70% using a cyclophi-
lin inhibitor (NIM811), which decreased graft injury and stimu-
lated liver regeneration by inhibiting CypD and MPTP [81]. An
additional beneﬁt of cyclophilin inhibition in small-for-size liver
transplantation is the marked reduction of associated pulmonary
injury [82]. NIM811 treatment profoundly reduced the expression
of inﬂammatory cytokines and adhesion molecules (TNF-alpha,
IL-1b, and ICAM-1), and as a result decreased lung inﬂammation
and injury associated with small-for-size liver transplants [82].
Non-alcoholic steatohepatitis (NASH)
Hepatic mitochondrial dysfunction appears to contribute to liver
damage in NASH. Patients with NASH have an impaired ability to
synthesize ATP and there is a decrease in hepatic mitochondrial
DNA. The mechanism is unknown but it may involve TNF-alpha,
which has been found to increase the permeability of mitochon-
drial membranes (reviewed in [83]). Clinical evidence that cyclo-
philin inhibition reduces liver cell necrosis was obtained in thevol. 61 j 1166–1174
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ﬁrst-in-human study of NIM811 when given as monotherapy in
HCV-infected patients. Two-week treatment with ascending
doses of NIM811 given alone had no effect on HCV RNA levels,
however even at low doses it caused rapid normalization of
serum aminotransferases despite lack of the antiviral effect [63].Liver inﬂammation and ﬁbrosis
Apart from impacting liver cell death via CypD inhibition and cor-
rection of mitochondrial dysfunction, cyclophilin inhibitors exert
signiﬁcant anti-inﬂammatory activity by interacting with extra-
cellular cyclophilins. In response to inﬂammatory stimuli CypA,
CypB, and CypC are secreted in the extracellular space and these
extracellular cyclophilins interact with CD147 or EMMPRIN
(extracellular matrix metalloproteinase inducer) on leukocytes
[10]. Inhibition of extracellular cyclophilins has shown a strong
anti-inﬂammatory effect in various in vivomodels, indicating that
extracellular cyclophilins may represent an initial trigger for the
release of pro-inﬂammatory cytokines and leukocyte recruitment
[10,84]. This notion is strengthened by ﬁndings using an experi-
mental compound - a non-immunosuppressive cell-impermeable
cyclophilin inhibitor, which demonstrated, in several inﬂamma-
tory models, a strong anti-inﬂammatory effect as a result of inhi-
bition of extracellular cyclophilins and their interaction with
CD147 [84]. The marked effect of NIM811 in reducing lung
inﬂammation and injury, in parallel with decreasing hepatic
TNF-alpha and IL-1b expression, after small-for-size liver trans-
plantation is an example of such an anti-inﬂammatory effect with
a non-immunosuppressive cyclophilin inhibitor [82]. Similarly,
blocking extracellular CypA and CD147 interaction signiﬁcantly
reduced myocardial inﬂammation and macrophage recruitment,
and in addition a pronounced reduction of myocardial ﬁbrosis
was observed [85]. So far, there is very little information whether
cyclophilin inhibitors might impact liver ﬁbrosis – either by
interacting directly with liver stellate cells, or as a consequence
of their anti-inﬂammatory effects. In a rat model with carbon tet-
rachloride-induced liver ﬁbrosis, NIM811 was found to reduce
the expression of the tissue inhibitor of metalloproteinase-1,
transforming growth factor-b along with signiﬁcantly reducing
the enhanced CypB expression [86]. The ﬁrst clinical results that
provide a preliminary indication that cyclophilin inhibition may
have an antiﬁbrotic effect come from a prospective, randomized
study comparing CsA and tacrolimus for liver ﬁbrosis develop-
ment in 356 liver transplant recipients [87]. Among steroid-free
patients in the study, liver ﬁbrosis progression (score >2) was sig-
niﬁcantly less frequent (p = 0.029) with CsA, compared with
tacrolimus at one year post-transplant. Additional investigations,
involving more speciﬁc measurements of ﬁbrosis, are needed to
further clarify whether cyclophilin inhibitors have antiﬁbrotic
effects that would be of clinical beneﬁt.Acetaminophen liver toxicity
The toxicity of paracetamol/acetaminophen (APAP) is initiated by
the excess of its reactive metabolite N-acetyl-p-benzoquinone
imine (NAPQI), which binds cellular glutathione and leads to pro-
found mitochondrial glutathione depletion, while the remaining
NAPQI is available to covalently bind to cellular proteins espe-
cially in mitochondria [88]. The resulting mitochondrial oxidative
stress leads to mitochondrial DNA damage and opening of theJournal of Hepatology 2014mitochondrial PTP, followed by nuclear DNA fragmentation and
ultimately necrotic cell death with release of damage-associated
molecular patterns (DAMP) that trigger an inﬂammatory
response. Cyclophilins appear to be involved in APAP-induced
liver injury via two mechanisms – ﬁrst, mitochondrial toxicity
and secondly, immune-mediated inﬂammatory damage. Several
studies have provided experimental data that mitochondrial PTPs
are involved in APAP-induced liver toxicity and that CsA can pro-
tect mouse hepatocytes from APAP toxicity [89–91]. In cultured
human hepatocytes, acetaminophen toxicity was markedly
decreased with CsA or its non-immunosuppressive derivative
NIM811 through CypD and correction of the mitochondrial dys-
function, however this cytoprotective effect was lost after 16 h
[90]. In contrast to these ﬁndings, a recent investigation of the
role of CypD inhibition in a mouse model of APAP liver toxicity
produced partially controversial results [92]. APAP (600 mg/kg)
induced injury in the mouse liver was not prevented by genetic
ablation of CypD in Ppif/ mice, or by application of DEB025
(alisporivir) 10 mg/kg injected intraperitoneally 1.5 h after APAP
administration, indicating the contribution of a parallel pathway,
a CypD-independent mode of APAP-induced liver injury, which
involves peroxynitrite-mediated cell damage. The results from
this investigation differ from a similar study where hepatotoxic-
ity in mice was induced by APAP 200 mg/kg and CypD-deﬁcient
Ppif/ mice were completely protected against APAP-induced
liver injury and DNA fragmentation [93]. Oxidant stress and
peroxynitrite formation were blunted but not eliminated in
CypD-deﬁcient mice.
Another major cyclophilin, which is key to inﬂammatory
response and immune-mediated APAP-induced injury, is CypA.
Recent studies have demonstrated that mice lacking CypA were
resistant to acetaminophen toxicity [94]. When wild type mice
were injected with necrotic liver cells from mice lacking CypA,
the inﬂammatory responses that caused necrotic liver damage
were reduced. Conversely, the host inﬂammatory response was
increased when CypA was injected together with necrotic liver
cells. Antagonism of the extracellular receptor for CypA can also
reduce acetaminophen-induced liver injury [94]. In patients with
paracetamol induced liver damage, urinary CypA levels are signif-
icantly increased. Overall, the current evidence indicates the
involvement of two cyclophilins – CypD (as a key determinant
of mitochondrial functions) and CypA (as mediator of pro-inﬂam-
matory reactions) as major contributors for acetaminophen liver
toxicity, thus indicating that pharmacological blockade with non-
immunosuppressive cyclophilin inhibitors might be beneﬁcial in
reducing APAP-induced liver injury.Hepatocellular carcinoma
Enhanced expression of cyclophilins has been observed in differ-
ent types of cancer, in particular CypA was found to be upregu-
lated in hepatocellular carcinoma (HCC) [95,96]. CypA
overexpression induces resistance to hypoxia and to chemother-
apeutic agents such as cisplatin in cancer cells. Cyclophilin inhi-
bition with CsA or sanglifehrin A was shown to provide a
synergistic effect with cisplatin and to increase cell death in
HCC cells [97]. Preliminary data have indicated that cyclophilins
may play a role in the metastatic potential of liver cancer cells, as
well as in responsiveness to chemotherapy. CypB was shown to
protect tumour cells – also in p53-defective HCC cells – againstvol. 61 j 1166–1174 1171
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hypoxia and apoptosis induced by chemotherapeutic agents such
as cisplatin. CypB was found to be overexpressed in 78% and 91%
of human HCC and colon cancer tissues, respectively. These
results suggest that hypoxia-induced CypB expression stimulates
the survival of HCC via a positive feedback loop with HIF-1a [98].
The level of CypA expression in two HCC-derived cell lines was
shown to correlate with their metastatic capability, while ectopic
CypA expression was found to promote cell adhesion, chemotaxis
and lung metastasis in vivo, without affecting cell proliferation.
Microarray studies have identiﬁed 21 different genes related to
metastasis having altered expression proﬁle in relation to CypA
overexpression. The enhanced CypA expression in HCC cells
was suggested to promote HCC metastasis through upregulation
of the matrix metalloproteinases MMP3 and MMP9 [99]. Cyclo-
philin inhibitors could therefore constitute new agents that have
the potential to augment the activity of chemotherapeutic agents
against HCC and also to decrease the metastatic spread of cancer
cells [96].Perspective
Cyclophilins are ubiquitously expressed cellular proteins, which
appear to be involved in the pathogenesis of a variety of liver dis-
eases. Cyclophilin A is established as a host cofactor essential for
the HCV replication complex in hepatocytes, and it also appears
to be involved in the replication of HBV and in HBsAg production.
Cyclophilin D is a key regulator of the mitochondrial permeability
pores, thus regulating the calcium exchange between mitochon-
dria and cytosol with implications for cell survival or death. Sev-
eral cyclophilin inhibitors have been developed, which allow to
investigate the potential beneﬁt of cyclophilin inhibition as a
therapeutic approach in liver diseases.Conﬂict of interest
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